



Department of Nursing and 
Department of Cardiovascular and Thoracic Surgery 
Prof. JO Defraigne 
University Hospital of Liège, Belgium.  
M-G LAGNY, F. BLAFFART, ECCP CHU de Liège 
 
CPB AND AORTIC SURGERY 
 
The State of the Art 
From a Theoretical to a Practical 
Approach 




Michel JB, et al. 
Novel aspects of the pathogenesis of aneurysms oh the abdominal aorta in humans. 
Cardiovasc Res. 2011 Aprl 1;90(1):18-27 
Golledge J, Norman PE, 
 
§  Medical treatment 
 
Current status of medical management for abdominal aortic aneurysm.Atherosclerosis, 
2011. 217 (1):p.57-63. 
 
§  Endovascular aortic repair 
Nienaber CA, et al. 
Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt 
Grafts in Aortic Dissection (INSTEAD) trial. Circulation, 2009. 120(25):p.2519-28. 
 
Hao Z, et al. 
Endovascular stent-graft placement or open surgery for the treatment of acute type B aortic 
dissection: a meta-analysis. Ann Vasc Surg, 2012. 26(4):p.454-61. 
M-G LAGNY, F. BLAFFART, ECCP CHU de Liège 
 
AIM OF THE TOPIC 
M-G LAGNY, F. BLAFFART, ECCP CHU de Liège 
 
STATE-OF-THE-ART PAPER
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Acute type A aortic dissection is a lethal condition requiring emergency surgery. It has diverse presentations, and
the diagnosis can be missed or delayed. Once diagnosed, decisions with regard to initial management, transfer,
appropriateness of surgery, timing of operation, and intervention for malperfusion complications are necessary.
The goals of surgery are to save life by prevention of pericardial tamponade or intra-pericardial aortic rupture, to
resect the primary entry tear, to correct or prevent any malperfusion and aortic valve regurgitation, and if possi-
ble to prevent late dissection-related complications in the proximal and downstream aorta. No randomized trials
of treatment or techniques have ever been performed, and novel therapies—particularly with regard to extent of
surgery—are being devised and implemented, but their role needs to be defined. Overall, except in highly spe-
cialized centers, surgical outcomes might be static, and there is abundant room for improvement. By highlight-
ing difficulties and controversies in diagnosis, patient selection, and surgical therapy, our over-arching goal
should be to enfranchise more patients for treatment and improve surgical outcomes. (J Am Coll Cardiol
2011;58:2455–74) © 2011 by the American College of Cardiology Foundation
Acute type A aortic dissection (ATAAD) is highly lethal
and might be increasing in incidence (1). Surgery is believed
to save and extend life, but despite apparent advances,
diagnosis is often delayed, evidence for improving outcomes
is modest (2), and optimal surgical management remains
unclear (3–8). Recent reviews (6,7,9–12) have directed
limited attention to the provision and performance of
surgery. This review specifically examines areas of uncer-
tainty and controversy in diagnosis, provision of care, and
surgical management of ATAAD and has the objectives of
promoting investigation to detect and treat the condition
earlier and to improve treatment outcomes.
Anatomy and Incidence
By definition,ATAAD involves the ascending aorta (AscAo) and
includes types I and II of the DeBakey classification. The
DeBakey classification categorizes dissections as type I
(involving the AscAo with distal extension), type II affecting
the AscAo only, and type III delineating disease of the
descending aorta (DescAo) and beyond. Modifications of
these classifications—which describe patho-anatomical
variants—exist, but for practical purposes, the original
classifications by specifying AscAo involvement and hence
risk of intra-pericardial rupture define those cases requiring
surgery (Fig. 1).
Neither classification dictates the site of the originat-
ing entry tear. In ATAAD a primary intimal tear is
usually present within the AscAo, sometimes accompa-
nied by secondary, more distal tears (13). In others,
involvement of the AscAo is due to retrograde propaga-
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CPB for aortic surgery: 
state of the art 
§  Knowledge 
§  Anatomical and pathophysiological pre-requests 
§  Flexibility 
§  Equipment 
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The arterial cannulation 
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Arterial cannulation complication and 
perfusion: local dissection 
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SWITCH TO ANOTHER CANNULATION SITE 
 
Anticipation: Y Line 
 
Arterial cannulation complication and 
perfusion: malperfusion (FLAP) 
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§  Sudden increase of arterial line pressure 
§  Inequate cerebral perfusion?: NIRS, TCD 
§  Inadequate spinal cord perfusion (MEP) 
§  Late diagnostic (lactates) 
§  Left radial pressure 
                
 
 
Pre and post arch arterial lines 
(+ left femoral) 
Swich to another cannulation site 




Arterial femoral cannulation complication 
and perfusion: false lumen 
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§  Pressure monitoring 
§  Transesophagal echocardiography(TOE) 
§  Arterial pressure (left radial) 
 
                
 
 
CHECK THE CANNULATION  




Arterial cannulation complication and 
perfusion: embolic event 
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§  Doppler 
§  Specific cannula 
 
                 
 
 
Volume 32, Number 4, 2005516 Aortic Cross-Clamping and Particulate Emboli
tion before aortic declamping would increase the num-
ber of particles captured and thus further minimize the
risk of systemic embolism.
Patients and Methods
Patients
From November 2002 through January 2003, 15
consecutive patients underwent elective CABG, valve
surgery, or both, with intra-aortic filtration at 2 dif-
ferent times, in accordance with our study protocol.
The hospital ethics committee approved the study,
and signed consent was obtained from all patients.
Three women and 12 men were enrolled in the
study (mean age, 71.6 ± 11.5 years; range, 50–93
years); 9 of the 15 patients (60%) were older than 70
years. Table I presents preoperative characteristics of
the 15 patients. Four patients underwent CABG alone
for multivessel coronary artery disease, and the other
11 underwent left-sided intracardiac procedures alone
or in combination with CABG: mitral valve annu-
loplasty (MVA; 1 patient), aortic valve replacement
(AVR; 7 patients), and AVR and CABG for single-
vessel disease (3 patients).
All surgical interventions included cardiopulmo-
nary bypass with complete systemic hemodilution
and normothermia or mild hypothermia, according
to standard techniques.
The Intra-Aortic Filter
The intra-aortic filter device (EMBOL-X®, Slim Pro-
tection System, Edwards Lifesciences; Irvine, Calif )
consists of a 24F metal-tipped aortic cannula that has
been modified with a side port so that a collapsible
filter can be inserted into and retracted from the aor-
ta, in a position immediately distal to the aortic cross-
clamp but proximal to the arterial return cannula and
the brachiocephalic artery (Fig. 1). The filter itself
consists of a heparin-coated polyester mesh that can
capture particles larger than 120 µm in diameter. The
filter is mounted on a flexible frame so that it can con-
form to the interior diameter of the ascending aorta
(Fig. 2). The risks associated with the use of this intra-
aortic filter are iatrogenic injury and aortic dissection.
Study Design
For each patient, the size of the filters to be used was
estimated by measuring the diameter of the internal
ascending aorta with use of transesophageal echocar-
diography (TEE). The filter size was ultimately cho-
sen by using an external sizer.
In each patient, before the aorta was clamped, the
1st filter (Filter A) was deployed into the aorta via the
cannula’s side port and was extracted approximately 5
minutes later. The filter was then inspected macro-
scopically and placed in a formalin solution. Before
the aorta was declamped, a 2nd filter (Filter B) was
deployed and was kept in place until the heart was
fully ejecting. Then this filter was also extracted, in-
spected macroscopically, and placed in a formalin so-
lution. All 30 f ilters were subsequently sent to an
Fig. 1 Schematic drawing shows the deployment and location
of the intra-aortic filter.
TABLE I. Preoperative Patient Characteristics (n=15
Patients)
Characteristics Number







Pre-CPB serum creatinine 85.6 ± 24.2
(µmol/L), mean ± SD (58.0–141.0)
range
Lipid index**
Pathologic (>5) 7 (47%)
Normal (5 or less) 8 (53%)
**Body mass index (BMI) = body weight in kilograms / height
in meters2
**Lipid index = [Total serum cholesterol (mmol/L) / HDL cho-
lesterol (mmol/L)] – [Serum triglycerides (mmol/L) / 2.2]
CPB = cardiopulmonary bypass
Cerebral protection 
Protecting the brain during aortic        
surgery: an enduring debate with 
unanswered questions. 
 
Stein LH, Elefteriades JA, 
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Selective cerebral perfusion: 
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Antegrade  selective cerebral perfusion: 
Complications and monitoring 
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Pro Cons Monitoring 




Embolic load Doppler 
Cerebral oedema in case 
of overflow and or over 
pressure 
 
Flow and pressure control 
Integrity of the circle of 








(S100 protein; NSE) 
Retrograde cerebral perfusion: 
complications and monitoring 
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Pro Cons monitoring 
 Easy of access Poor control of flow 
delivery, 
Dispertion of the flow 
through the Azygos vein 
NIRS, transcranial 
doppler 
Retrograde flush of the 
carotids 
Cerebral oedema in case 
of overflow 
And or overpressure 
Flow control and Venous 
pressure (30 mmHg) 
Deep hypothermia circulatory arrest: 
state of the art 
 
§  Respect of temperatures gradients (6-10°C max) 
§  Normoxia 
§  Hct level versus viscosity (25% Hct max) 
§  Homogenization of temperatures (cerebral and systemic) 
§  Hardware:                                             
                      Heater cooler device 
                      Efficient heat exchanger 
                      Cooling helmet 
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Deep hypothermia circulatory arrest: 
state of the art:blood gases management 
     
 
      alpha-stat stategy (adult surgery) 














An evidence-based review of the practice of cardiopulmonary
bypass in adults: A focus on neurologic injury, glycemic
control, hemodilution, and the inflammatory response
Kenneth G. Shann, CCP,a Donald S. Likosky, PhD,b John M. Murkin, MD,c Robert A. Baker, PhD CCP(Aust),d
Yvon R. Baribeau, MD,e Gordon R. DeFoe, CCP,b Timothy A. Dickinson, MS,f Timothy J. Gardner, MD,g Hilary P. Grocott, MD,h
Gerald T. O’Connor, PhD, DSc,b David J. Rosinski, CCP,i Frank W. Sellke, MD,j and Timothy W. Willcox, CCP(Aust)k
Supplemental material is
available online.
Cardiopulmonary bypass (CPB) can be used during cardiac surgery to oxy-genate and subsequently recirculate blood that has been diverted from theheart and lungs. The practice of CPB has changed—and continues to
change—dramatically since its advent in the 1950s. Although structured reviews of
the evidence supporting the practice of cardiac surgery have been in the literature for
more than a decade and continue to be refined in the wake of new and emerging
evidence,E1,E2  additional  targeted  reviews,  focusing on  issues  such as minimizing
the effect of the inflammatory response or minimizing neurologic injury, are
warranted.E3-E5  Previous  attempts,  by  Edwards  and  colleaguesE6  and  Bartels  and
associates,E7 at synthesizing the evidence base to support the principles of CPB have
selectively reviewed the cardiac surgery literature or focused on unique patient
populations. Additionally, the development of these reviews has not involved all
members of the clinical team, most notably the individuals tasked with operating the
CPB circuit. This gap in knowledge is in stark contrast with the shared goal of the
cardiac team, namely to improve the conduct of CPB to reduce the patient’s risk of
adverse outcomes caused by cardiac surgery.
Despite a preponderance of evidence supporting key principles of managing safe
and effective CPB practice, wide variation in the use of technology and techniques
for  conducting  CPB  persists  regionally  and  nationally.E8,E9  Variations  in  practice
have previously been shown to be associated with increased costs, lengths of stay,
neurologic  injury,  and mortality.1-3,E5,E10,E11  This variation might be attributed  to
clinical uncertainty or institutional or local practice standards. To reduce this
unwanted practice variation, we must provide our clinical colleagues with critically
evaluated and evidence-based review for conducting CPB.
What follows is an evidence-based review for conducting safe, patient-centered,
and effective CPB practice. The authors have graded the level of evidence and
classified the findings listed below by using the criteria promulgated by the Amer-
ican Heart Association and the American College of Cardiology Task Force on
Practice Guidelines  (Table 1). The development of  these findings evolved  from a
structured MEDLINE search coupled with critical review of the peer-review liter-
ature and debates stemming from presentations at regional and national conferences,
including the Connecticut Society of Perfusion (2004), Outcomes 2004: The Key
West Meeting, New York State Society of Perfusion (2004), 12th Annual Meeting
on Optimization of Blood Management During Surgery (2004), Florida State
Society of Perfusion (2004), Tennessee State Society of Perfusion (2004), American
Academy of Cardiovascular Perfusion (2005, 2006), and Outcomes 2005: The Key
West Meeting.
The authors, a multidisciplinary group of physicians, epidemiologists, and per-
fusionists, seek to develop and share evidence-based reviews for conducting CPB
through rigorous, structured, and expert-driven analysis of the peer-reviewed liter-
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The life-saving benefits of cardiac surgery are frequently 
accompanied by negative side effects, such as stroke, which 
is one of the most devastating and significant neurological 
complications. The incidence of this complication varies 
according to type of surgery, from 2% after coronary artery 
bypass grafting (CABG) to up to 13% following aortic sur-
gery.1,2 Stroke is associated with substantial increases in 
mortality, length of hospitalization, and use of intermediate- 
or long-term care facilities, with estimated costs of $43 
billion per year for the United States.3
Stroke presents either as early neurological injury imme-
diately after surgery or, in more than half of the patients, as 
delayed stroke within the first few days postoperatively. 
Early strokes are most likely caused by embolic events, 
whereas delayed strokes may be related to atrial fibrillation 
and/or coagulopathy during the postoperative period.4
Although stroke presents commonly as a severe compli-
cation after cardiac surgery, no guidelines for any routine 
use of neuroprotective drugs or strategies have yet been 
established.5 Stroke during cardiac surgery may be avoided 




Neuromonitoring during cardiac surgery assists in detecting 
injurious events and may minimize secondary cerebral dam-
age. Near infrared spectroscopy (NIRS) is a noninvasive 
tool to measure regional tissue oxygen saturation and 
Avoiding Stroke During 
Cardiac Surgery
Kristine Kellermann, DVM1, and Bettina Jungwirth, MD1
Abstract
The life saving benefits of cardiac surgery are frequently accompanied by negative side effects such as stroke, that occurs 
with an incidence of 2%-13% dependent to type of surgery. The etiology is most likely multifactorial with embolic events 
considered as main contributor. Although stroke presents a common complication, no guidelines for any routine use of 
pharmacological substances or non-pharmacological strategies exist to date. 
Non-pharmacological strategies include monitoring of brain oxygenation and perfusion with devices such as near 
infrared spectroscopy and Transcranial Doppler help. Epiaortic and transesophageal echocardiography visualize aorta 
pathology, enabling the surgeon to sidestep atheromatous segments. Additionally can the use of specially designed aortic 
cannulae and filters help to reduce embolization. Brain perfusion can be improved by using antero- or retrograde cerebral 
perfusion during deep hypothermic circulatory arrest, by tightly monitoring mean arterial blood pressure and hemodilu-
tion. Controlling perioperative temperature and glucose levels may additionally help to ameliorate secondary damage.
Many pharmacological compounds have been shown to be neuroprotective in preclinical models, but clinical studies 
failed to confirm these results so far.
Remacemide, an NMDA-receptor-antagonist showed a significant drug-based neuroprotection during cardiac surgery. 
Other substances currently assessed in clinical trials whose results are still pending are acadesine, an adenosine-regulating 
substance, the free radical scavenger edaravone and the local anesthetic lidocaine.
Stroke remains as significant complication after cardiac surgery. Non-pharmacological strategies allow perioperative 
caregivers to detect injurious events and to ameliorate stroke and its sequelae. Considering the multi-factorial etiology 
though, stroke prevention will likely have to be addressed with an individualistic combination of different strategies and 
substances. 
Keywords
approach, cardiac surgery, stroke
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Deep hypothermia circulatory 
arrest and reperfusion injury 
§  Low pressure 
§  Normoxia 
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Deep hypothermic circulatory arrest and global reperfusion
injury: Avoidance by making a pump prime reperfusate—A
new concept
Bradley S. Allen, MD
Jeffrey S. Veluz, MD
Gerald D. Bu kberg, MD
Ernesto Aeberhard, MD, PhD
Louis J. Ignarro, MD
See related editorial on page
460.
Objective: We sought to determine whether damage after deep hypothermic circu-
latory arrest can be diminished by changing pump prime components when rein-
stituting cardiopulmonary bypass.
Methods: Fifteen piglets (2-3 months old) were cooled to 19°C by using the alpha-stat
pH strategy. Five were cooled and rewarmed without ischemia (control animals), and
the other 10 piglets underwent 90 minutes of deep hypothermic circulatory arrest. Of
these, 5 were rewarmed and reperfused without altering the cardiopulmonary bypass
circuit blood prime. In the other 5 animals, the bypass blood prime was modified
(leukocyte depleted, hypocalcemic, hypermagnesemic, pH-stat, normoxic, mannitol,
and an Na!/H! exchange inhibitor) during circulatory arrest before starting warm
reperfusion. Oxidant injury was assessed on the basis of conjugated dienes, vascular
changes on the basis of endothelin levels, myocardial function on the basis of cardiac
output and dopamine need, lung injury on the basis of pulmonary vascular resistance
and oxygenation, and cellular damage on the basis of release of creatine kinase and
aspartate aminotransferase. Neurologic assessment (score 0, normal; score 500, brain
death) was done 6 hours after discontinuing cardiopulmonary bypass.
Results: Compared with animals undergoing cardiopulmonary bypass without isch-
emia (control animals), deep hypothermic circulatory arrest without modification of
the reperfusate produced an oxidant injury (conjugated dienes increased 0.78 vs 1.71
absorbance (Abs) 240 nmol/L per 0.5 mL, P " .001 vs control animals), depressed
cardiac output (6.0 vs 4.0 L/min, P " .05 vs control subjects), prolonged dopamine
need (P " .001 vs control subjects), elevated pulmonary vascular resistance (74%
vs 197%, P " .05 vs control subjects), reduced oxygenation (P " .01 vs control
subjects), increased neurologic injury (56 vs 244, P" .001 vs control subjects), and
increased release of creatine kinase (2695 vs 6974 U/L, P" .05 vs control subjects),
aspartate aminotransferase (144 vs 229 U/L), and endothelin (1.02 vs 2.56 pg/mL,
P " .001 vs control subjects). Conversely, the oxidant injury was markedly limited
(conjugated dienes of 0.85 # 0.09 Abs 240 nmol/L per 0.5 mL, P " .001 vs
unmodified pump prime) with modification of cardiopulmonary bypass prime,
resulting in increased cardiac output (5.1 # 0.8 L/min), minimal dopamine need
(P" .001 vs unmodified pump prime), no increase in pulmonary vascular resistance
(44%# 31%, P" .01 vs unmodified pump prime) or endothelin levels (0.64# 0.15
pg/mL, P " .001 vs unmodified pump prime), complete recovery of oxygenation
(P " .01 vs unmodified pump prime), reduced neurologic damage (144 # 33, P "
.05 vs unmodified pump prime), and lower release of aspartate aminotransferase
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Descending aortic surgery: CPB circuit 
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Left-left bypass 
  Left-right bypass 
Conventional miniaturizated CPB 
Left atrium – distal aorta 
Right atrium distal aorta 
 
Right atrium (femoral access) – distal aorta 
Centrifugal pump  
Autoregulation of the volemia 
 
Centrifugal or roller pump 
Heat exchanger + oxygenator 
Low heparin level 
 
Full heparinized 
Easy shunt for selective perfusion 
Quick response to acute hemorrhagic event 
Surgery on the descending aorta medullar 
and splanchnic selective perfusion 
•  Perfusion  
•  Local hypothermia 
•  Systemic mild hypothermia  
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Medullar and splanchnic perfusion: 
complications and monitoring 
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[JL Complications monitoring 
Local dissection Q-Pressure 
oedema in case of overflow 
and or over pressure or brain 
herniation 





Flow, regional pressure (60mmHg),   
Doppler flowmetry 
MEP (motor evoquated potential).  
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Thromboelastometry-guided administration of fibrinogen
concentrate for the treatment of excessive intraoperative bleeding in
thoracoabdominal aortic aneurysm surgery
Niels Rahe-Meyer, MD, MSc, PhD,a Cristina Solomon, MD,a Michael Winterhalter, MD,a
Siegfried Piepenbrock, MD,a Kenichi Tanaka, MD, MSc, PhD,b Axel Haverich, MD,c and
Maximilian Pichlmaier, MDc
Objective: Thoracoabdominal aortic aneurysm operations are associated with extensive blood loss and high
requirements for allogeneic blood product transfusion. We assessed the efficacy of intraoperative post–cardiopul-
monary bypass administration of fibrinogen concentrate in elective thoracoabdominal aortic aneurysm surgery.
Methods: In a retrospective group (group A, n ¼ 12) of patients undergoing elective thoracoabdominal aortic
aneurysm surgery, clinically relevant diffuse bleeding after weaning from cardiopulmonary bypass was treated
with allogeneic blood products (platelet concentrates, followed by fresh frozen plasma) according to a predeter-
mined algorithm.
In a prospective group (group F, n¼ 6) a first therapy step with fibrinogen concentrate was added to the algorithm.
The dose of fibrinogen concentrate was estimated by using thromboelastometric data (ROTEM FIBTEM). Before
each step of hemostatic therapy, blood loss in the range of 60 to 250 g per 5 minutes was confirmed.
Results: In group F, administration of 7.8 " 2.7 g of fibrinogen concentrate established hemostasis, completely
avoiding intraoperative transfusion of fresh frozen plasma and platelet concentrates. Transfusion of blood prod-
ucts after cardiopulmonary bypass and during the 24 hours after surgical intervention was markedly lower in
group F than in group A (2.5 vs 16.4 units; 4/6 patients in group F required no transfusion of blood products),
as was 24-hour drainage volume (449 vs 1092 mL). Fibrinogen plasma levels, standard coagulation parameters,
and hemoglobin and hematocrit values were comparable between the 2 groups on the first postoperative day.
Conclusions: FIBTEM-guided post–cardiopulmonary bypass administration of fibrinogen concentrate resulted
in improved intraoperative management of coagulopathic bleeding in thoracoabdominal aortic aneurysm opera-
tions and reduced transfusion and 24-hour drainage volume.
Thoracoabdominal aortic aneurysm (TAAA) operations are
frequently complicated by excessive perioperative bleeding,
most commonly caused by impairment of the coagulation
system.1Patientswith aortointimal disease are in ahyperfibri-
nolytic state because of abnormal endothelial expression of
tissue plasminogen activator, which correlates with the
chronic consumption coagulopathy accompanying aortic an-
eurysm.2 Extracorporeal circulation (ECC) exerts an addi-
tional deleterious effect on hemostasis through activation
of coagulation and fibrinolysis, consumption coagulopathy,
and decreased platelet function.3,4 Excessive bleeding en-
hances the risk of rethoracotomy, transfusion, or periopera-
tive myocardial infarction, leading to increased morbidity
and mortality.5 Although TAAA surgery has improved
over recent years, the perioperative consumption of alloge-
neic blood products and the risk of bleeding remain high.6
The standard hemostatic treatment is transfusion of nonery-
throcyte allogeneic blood products: fresh frozenplasma (FFP),
platelet concentrates (PCs), and, in some countries, cryopreci-
pitate. However, there is an inherent risk of transmission of
pathogens with transfusion of allogeneic blood products,
which can be associated with serious adverse effects.7,8 Pre-
emptive transfusion, in which blood products are transfused
before laboratory abnormalities are recognized, plays a central
role in the intraoperative transfusion strategy for TAAA oper-
ations and has shown improved outcome comparedwith treat-
ment algorithms based on laboratory measurements.9
The possibilities for reducing transfusion of allogeneic
blood products after cardiac surgery have been investigated
recently. Assessment of clot formation and strength, mea-
sured by using viscoelastic methods (thromboelastography
[TEG] or thromboelastometry [ROTEM]), is useful for
the diagnosis of intraoperatively acquired coagulation
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Perioperative Management Rahe-Meyer et al
Blood management 
§  Selective suction blood management 
§  Specific filtration 
§   Cell saving process 
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Conclusions 
§  Aorta surgery is a team work 
§  Multiple modal approaches 
§  Engering developments 
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